As global markets navigate a mixed start to the new year, with U.S. stocks experiencing both gains and declines and notable economic indicators like the Chicago PMI showing contraction, investors are keenly observing opportunities for value amidst volatility. In such an environment, identifying undervalued stocks can be particularly appealing as these equities may offer potential for growth when broader market conditions stabilize or improve.
Name | Current Price | Fair Value (Est) | Discount (Est) |
Avant Group (TSE:3836) | ¥1878.00 | ¥3755.66 | 50% |
NBTM New Materials Group (SHSE:600114) | CN¥15.55 | CN¥31.07 | 49.9% |
Gaming Realms (AIM:GMR) | £0.36 | £0.72 | 49.9% |
Sudarshan Chemical Industries (BSE:506655) | ₹1120.30 | ₹2232.36 | 49.8% |
Kinaxis (TSX:KXS) | CA$170.99 | CA$340.11 | 49.7% |
ReadyTech Holdings (ASX:RDY) | A$3.15 | A$6.30 | 50% |
Vogo (ENXTPA:ALVGO) | €2.94 | €5.87 | 49.9% |
Exosens (ENXTPA:EXENS) | €22.505 | €44.77 | 49.7% |
iFLYTEKLTD (SZSE:002230) | CN¥45.41 | CN¥90.65 | 49.9% |
Salmones Camanchaca (SNSE:SALMOCAM) | CLP2434.90 | CLP4848.26 | 49.8% |
Click here to see the full list of 885 stocks from our Undervalued Stocks Based On Cash Flows screener.
Let's dive into some prime choices out of the screener.
Overview: CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally, with a market cap of SEK4.93 billion.
Operations: The company's revenue is primarily derived from automated microscopy systems and reagents in the field of hematology, totaling SEK737.16 million.
Estimated Discount To Fair Value: 39.3%
CellaVision AB is trading at SEK 206.5, significantly below its estimated fair value of SEK 340.38, indicating substantial undervaluation based on cash flows. The company reported strong earnings growth of 33.9% over the past year and forecasts suggest continued robust earnings growth at 22.5% annually, outpacing the Swedish market's average growth rate. Recent financial results show increased revenues and net income for Q3 and nine months ending September 2024, reinforcing its positive cash flow outlook.
Overview: Digital China Holdings Limited is an investment holding company that offers big data products and solutions to government and enterprise customers mainly in Mainland China, with a market capitalization of approximately HK$5.20 billion.
Operations: The company's revenue is derived from three main segments: Big Data Products and Solutions (CN¥3.39 billion), Software and Operating Services (CN¥5.31 billion), and Traditional and Localization Services (CN¥10.03 billion).
Estimated Discount To Fair Value: 46.2%
Digital China Holdings is trading at HK$3.11, significantly below its estimated fair value of HK$5.78, highlighting potential undervaluation based on cash flows. The company is projected to achieve profitability within three years, with revenue growth forecasted at 8.8% annually—outpacing the Hong Kong market's average rate of 7.5%. Despite a low future return on equity of 7.6%, Digital China presents good relative value compared to peers and industry standards.
Overview: Pruksa Holding Public Company Limited, with a market cap of THB15.76 billion, operates through its subsidiaries to develop and sell residential real estate properties in Thailand.
Operations: The company's revenue segments include SBU Hospital with THB2.32 billion, SBU Townhouse with THB6.32 billion, SBU Condominium with THB5.74 billion, and SBU Single House with THB6.43 billion.
Estimated Discount To Fair Value: 11.4%
Pruksa Holding, trading at THB7.2, is slightly undervalued compared to its fair value of THB8.13 based on cash flows. Earnings are expected to grow significantly at 28.4% annually, surpassing the Thai market's average growth rate of 16.6%. However, profit margins have declined from 11.3% last year to 4.3%, and the dividend yield of 11.11% is not well covered by earnings, indicating potential risks despite promising revenue growth forecasts of 8.9%.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include OM:CEVI SEHK:861 and SET:PSH.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。